摘要
本文通过对2012年-2018年肿瘤科已结束的3个抗肿瘤药物临床试验进行总结。分析在抗肿瘤药物临床试验启动、进行、结束不同阶段,专职研究护士与药物临床试验各方进行沟通的主要内容及采取方法的个体化特点。探讨专职研究护士如何在抗肿瘤药物临床试验中,更好的发挥在PI和研究者、申办方(监查员)、医院药物临床试验机构、受试者之间的沟通桥梁作用,促进抗肿瘤药物临床试验更高质量的完成。推动专职研究护士在抗肿瘤临床试验中的发展,激励更多护士从事抗肿瘤药物临床试验专职研究护士。
The article summarizes three clinical tests of anti-tumor drugs that have ended in oncology department from 2012 to 2018,analyzes main contents and individual characteristics of methods during communication between full-time research nurses and the parties of drug clinical tests at different stages of start,duration,and end of anti-tumor drug clinical tests.It explores how full-time research nurses can better play role of communication bridge between PI and researchers,sponsors(supervisors),hospital drug clinical trial institutions,and objects in anti-tumor drug clinical tests,to promote higher quality completion of anti-tumor drug clinical tests,and development of full-time research nurses in anti-tumor clinical tests,and encourage more nurses to engage in full-time research nurses in anti-tumor drug clinical tests.
作者
祝婕
柏雪
罗成姣
黄代清
张桂萍
ZHU Jie;BAI Xue;LUO Cheng-jiao;HUANG Dai-qing;ZHANG Gui-ping(Guizhou University of Traditional Chinese Medicine,Guiyang,Guizhou 550025;Guizhou Provincial People’s Hospital,Guiyang,Guizhou,550002)
出处
《智慧健康》
2020年第15期29-30,52,共3页
Smart Healthcare
关键词
研究护士
临床试验
个体化
沟通
Research nurse
Clinical test
Individualization
Communication
